Semper Paratus Acquisition (NASDAQ:TVGN) Shares Down 2.4% - Here's What Happened

Semper Paratus Acquisition Corporation (NASDAQ:TVGN - Get Free Report) shares traded down 2.4% on Tuesday . The stock traded as low as $1.20 and last traded at $1.22. 313,027 shares were traded during trading, a decline of 94% from the average session volume of 5,060,446 shares. The stock had previously closed at $1.25.

Analyst Ratings Changes

Separately, D. Boral Capital reiterated a "buy" rating and issued a $10.00 target price on shares of Semper Paratus Acquisition in a research note on Wednesday, June 18th.

Semper Paratus Acquisition Stock Up 2.5%

The firm's 50 day moving average is $1.18 and its 200-day moving average is $1.21.

Insider Activity at Semper Paratus Acquisition

In related news, CEO Ryan H. Saadi sold 1,438,206 shares of the firm's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $1.23, for a total value of $1,768,993.38. Following the transaction, the chief executive officer directly owned 116,814,453 shares of the company's stock, valued at approximately $143,681,777.19. This trade represents a 1.22% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 73.24% of the company's stock.

Hedge Funds Weigh In On Semper Paratus Acquisition

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Barclays PLC grew its stake in Semper Paratus Acquisition by 39.2% in the 4th quarter. Barclays PLC now owns 45,600 shares of the company's stock valued at $48,000 after buying an additional 12,847 shares during the last quarter. Northern Trust Corp lifted its position in shares of Semper Paratus Acquisition by 13.0% during the 4th quarter. Northern Trust Corp now owns 118,415 shares of the company's stock worth $122,000 after purchasing an additional 13,595 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Semper Paratus Acquisition by 74.2% during the 4th quarter. JPMorgan Chase & Co. now owns 39,207 shares of the company's stock valued at $40,000 after purchasing an additional 16,695 shares during the period. Geode Capital Management LLC grew its holdings in Semper Paratus Acquisition by 31.2% in the 4th quarter. Geode Capital Management LLC now owns 451,851 shares of the company's stock valued at $465,000 after buying an additional 107,566 shares during the last quarter. Finally, XTX Topco Ltd acquired a new position in shares of Semper Paratus Acquisition during the fourth quarter worth approximately $55,000.

Semper Paratus Acquisition Company Profile

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.